← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Enzymes
laronidase
A16AB05
Forms & Strengths
- Injection: 2.9 mg/5 mL solution in single-use vials
Adult Dosing
- 0.58 mg/kg IV once weekly infused over approximately 3 to 4 hours
Pediatric Dosing
- Patients 5 years and older: 0.58 mg/kg IV once weekly infused over approximately 3 to 4 hours
- Safety and efficacy in pediatric patients under 5 years have not been established
Indications
- Enzyme replacement therapy for patients with Mucopolysaccharidosis I (MPS I) including Hurler and Hurler-Scheie forms, and Scheie phenotype
Mechanism of Action
- Recombinant human alpha-L-iduronidase (rhIDU) replaces deficient endogenous alpha-L-iduronidase enzyme
- Catabolizes glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate, reducing lysosomal accumulation
Contraindications
- Life-threatening hypersensitivity reactions to laronidase or excipients when rechallenge is unsuccessful
Adverse Reactions
- Infusion-associated reactions (fever, chills, rigors, hypotension, urticaria, dyspnea)
- Upper respiratory tract infection
- Rash
- Paresthesia
- Injection site reactions
Drug Interactions
- Formal clinical pharmacokinetic drug-drug interaction studies have not been performed with laronidase
Curated Content: Needs Vetting Before Put to Clinical Use